Oramed Pharmaceuticals Inc. (ORMP)

Oramed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	15.25	45.95	54.42	9.06	40.46	27.46
Short-Term Investments	35.37	79.95	87.51	152.99	115.26	118.82
Cash & Short-Term Investments	50.61	125.89	141.93	162.05	155.72	146.28
Cash Growth	-48.32%	-11.30%	-12.41%	4.06%	6.45%	55.39%
Other Receivables	1.4	0.45	-	-	-	-
Receivables	1.4	5.09	-	-	-	-
Prepaid Expenses	0.93	2.29	1.29	0.54	1.39	1.66
Total Current Assets	53.41	133.27	143.22	162.58	157.11	147.94
Property, Plant & Equipment	1.15	1.34	1.11	1.57	1.8	0.89
Long-Term Investments	312.67	93.74	10.91	56.37	2.7	3.88
Other Long-Term Assets	1.97	1.97	0.03	0.03	0.03	25.12
Total Assets	369.64	230.86	155.28	220.55	161.64	177.82

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.37	0.44	0.79	0.55	2.18	1.69
Accrued Expenses	1.86	3.12	1.48	1.38	1.97	2.31
Short-Term Debt	-	-	-	51.01	-	-
Current Portion of Leases	0.25	0.29	0.22	0.27	0.25	0.13
Current Income Taxes Payable	6.27	3.29	3.2	-	-	-
Current Unearned Revenue	1.71	1.35	-	-	1.34	2.7
Other Current Liabilities	0.26	10.6	-	-	0.01	0.53
Total Current Liabilities	10.73	19.09	5.69	53.21	5.75	7.37
Long-Term Leases	0.48	0.54	0.16	0.34	0.65	0.37
Long-Term Unearned Revenue	1.21	3.27	4	4	4	3.34
Pension & Post-Retirement Benefits	0.04	0.04	0.03	0.03	0.02	0.02
Long-Term Deferred Tax Liabilities	39.54	7.91	-	-	-	-
Other Long-Term Liabilities	0.16	0.28	0.06	0.07	0.07	0.11
Total Liabilities	52.17	31.12	9.93	57.66	10.49	11.21

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.5	0.47	0.48	0.49	0.48	0.46
Additional Paid-In Capital	323.94	322.71	322.4	320.89	314.42	292.51
Retained Earnings	-6.97	-123.44	-176.62	-157.56	-163.08	-126.52
Total Common Equity	317.47	199.74	146.27	163.82	151.81	166.45
Minority Interest	-	-	-0.92	-0.93	-0.66	0.16
Shareholders' Equity	317.47	199.74	145.35	162.89	151.16	166.61
Total Liabilities & Equity	369.64	230.86	155.28	220.55	161.64	177.82

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.73	0.83	0.37	51.62	0.89	0.5
Net Cash (Debt)	71.75	133.44	141.56	112.23	154.83	149.66
Net Cash Growth	-26.06%	-5.73%	26.13%	-27.51%	3.45%	49.21%
Net Cash Per Share	1.70	3.15	3.47	2.77	3.97	4.03
Filing Date Shares Outstanding	41.6	40.45	40.85	40.52	39.78	38.56
Total Common Shares Outstanding	41.31	39.28	39.92	40.34	39.56	38.16
Working Capital	42.68	114.19	137.54	109.37	151.36	140.57
Book Value Per Share	7.68	5.09	3.66	4.06	3.84	4.36
Tangible Book Value	317.47	199.74	146.27	163.82	151.81	166.45
Tangible Book Value Per Share	7.68	5.09	3.66	4.06	3.84	4.36

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error